Latest News - Biogen

Friday, October 27, 2017 | Clinical Trials, Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Biogen

ECTRIMS: First-in-Class Monoclonal Antibody Shows Promise in Phase 2 Data

Results from the Phase 2 SYNERGY trial suggest that the investigational opicinumab (Biogen) could have an increased clinical effect in patients with relapsing multiple sclerosis (MS) who had the disea…

Read the full story

Thursday, September 15, 2016 | Research and Publications, Biogen

ECTRIMS: Results from DECIDE Trial Affirm Benefits of Zinbryta

A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with Zinbryta (daclizumab, Biogen/AbbVie) achieved no evidence of disease activity (NE…

Read the full story

Tuesday, August 09, 2016 | Phase 3/4 Trials, Biogen

Investigational BACE Inhibitor for Early Alzheimer’s Disease Moves to Phase 3 Trials

An investigational BACE inhibitor for the treatment of early Alzheimer’s disease is moving into Phase 3 trials, following confirmation from the FDA. Developed in a partnership between Eisai and …

Read the full story

Saturday, May 28, 2016 | FDA Approval/Clearance, Biogen

Once-Monthly Self-Administered Multiple Sclerosis Treatment Zinbryta Wins FDA Approval

The FDA has approved Zinbryta (daclizumab, Biogen/AbbVie), a once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS). The approval of Zinbryta is p…

Read the full story